KalVista Pharmaceuticals (KALV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 25. Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on the stock and has a $18.00 price target.
Joseph Schwartz has given his Buy rating due to a combination of factors, primarily focusing on the promising commercial strategy and potential market impact of KalVista Pharmaceuticals’ lead asset, sebetralstat. The company is advancing this oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE), with a New Drug Application already accepted and a PDUFA action date set for June 2025. KalVista’s comprehensive preparation for the potential commercial launch, as highlighted in their recent webcast, underscores their readiness to capitalize on the market opportunity.
Schwartz also notes the significant market potential for sebetralstat, particularly due to its oral administration, which addresses the current shortcomings of existing intravenous treatments. The company’s early completion of enrollment in the KONFIDENT-KID pediatric HAE study further strengthens its position, as sebetralstat could fulfill an unmet need for younger patients. Despite the stock’s strong performance year-to-date, Schwartz sees additional upside potential, with the company’s enterprise value still below the projected peak sales estimates. This combination of strategic readiness and market opportunity underpins the Buy rating.
KALV’s price has also changed moderately for the past six months – from $9.460 to $12.500, which is a 32.14% increase.